High-dose Enerzair Breezhaler further cuts asthma exacerbations
New analysis shows high-dose, once-daily Enerzair Breezhaler cut asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose
Read More
Tag: glycopyrronium bromide
Novartis banks EC approval for Enerzair Breezhaler
The product includes the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
Read More
Sosei get $2.5m for QVM149 MAA
The company recently announced positive data from two Phase II clinical studies, in which QVM149 was shown to be superior to the comparators.
Read More
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
- BioDuro and CTI Biotechnology form partnership to accelerate preclinical drug development
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
